The application of artificial intelligence to accelerate G protein‐coupled receptor drug discovery
British Journal of Pharmacology · 2024-07 · 181 (14) · 2371-2384
DOI: 10.1111/bph.16140 ↗At a glance
Übersichtsarbeit in British Journal of Pharmacology, published online on 2023-05-26. Written by Anh T N Nguyen and 9 co-authors. Institution: Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. Major MEDLINE topics: Receptors, G-Protein-Coupled, Drug Discovery, Artificial Intelligence. Cited 46 times so far (Crossref); 124 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Health and Medical Research Council, National Heart Foundation of Australia, The Cross Family and The Frank Alexander Charitable Trusts.
Abstract (original language)
The application of artificial intelligence (AI) approaches to drug discovery for G protein‐coupled receptors (GPCRs) is a rapidly expanding area. Artificial intelligence can be used at multiple stages during the drug discovery process, from aiding our understanding of the fundamental actions of GPCRs to the discovery of new ligand‐GPCR interactions or the prediction of clinical responses. Here, we provide an overview of the concepts behind artificial intelligence, including the subfields of machine learning and deep learning. We summarise the published applications of artificial intelligence to different stages of the GPCR drug discovery process. Finally, we reflect on the benefits and limitations of artificial intelligence and share our vision for the exciting potential for further development of applications to aid GPCR drug discovery. In addition to making the drug discovery process “faster, smarter and cheaper,” we anticipate that the application of artificial intelligence will create exciting new opportunities for GPCR drug discovery. LINKED ARTICLES This article is part of a themed issue Therapeutic Targeting of G Protein‐Coupled Receptors: hot topics from the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists 2021 Virtual Annual Scientific Meeting. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.14/issuetoc
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
- Department of Information Technology, Faculty of Engineering and Technology, Vietnam National University, Cau Giay, Hanoi, Vietnam.
- Monash Data Futures Institute and Department of Data Science and Artificial Intelligence, Monash University, Clayton, Victoria, Australia.
- Monash DeepNeuron, Monash University, Clayton, Victoria, Australia.
ORCID profiles: Lauren T May, Michelle L Halls
Funding
- National Health and Medical Research Council
- National Heart Foundation of Australia
- The Cross Family and The Frank Alexander Charitable Trusts
Cite
APA
Nguyen, A. T. N., Nguyen, D. T. N., Koh, H. Y., Toskov, J., MacLean, W., Xu, A., Zhang, D., Webb, G. I., May, L. T., & Halls, M. L. (2024). The application of artificial intelligence to accelerate G protein‐coupled receptor drug discovery. British Journal of Pharmacology, 181(14), 2371-2384. https://doi.org/10.1111/bph.16140
Vancouver
Nguyen ATN, Nguyen DTN, Koh HY, Toskov J, MacLean W, Xu A, et al. The application of artificial intelligence to accelerate G protein‐coupled receptor drug discovery. British Journal of Pharmacology. 2024;181(14):2371-2384. doi:10.1111/bph.16140
BibTeX
@article{Nguyen2024,
author = {Nguyen, Anh T N and Nguyen, Diep T N and Koh, Huan Yee and Toskov, Jason and MacLean, William and Xu, Andrew and Zhang, Daokun and Webb, Geoffrey I and May, Lauren T and Halls, Michelle L},
title = {The application of artificial intelligence to accelerate G protein‐coupled receptor drug discovery},
journal = {British Journal of Pharmacology},
year = {2024},
volume = {181},
number = {14},
pages = {2371--2384},
doi = {10.1111/bph.16140}
}
EUVIMED